MUMBAI, India — Shares of Sudarshan Pharma Industries fell more than 3 percent on Monday after the Goods and Services Tax department initiated an inspection, search and seizure operation at the company’s registered office.
The stock declined 3.06 percent on the BSE to an intraday low of Rs 25.62 per share and was trading at the same level at around 1:10 p.m. Over the past year, the company’s shares have fallen about 19 percent, according to exchange data.
The decline followed a regulatory filing in which the company disclosed that the GST department conducted an inspection, search and seizure operation at its registered office on February 21, 2026. Sudarshan Pharma said it is in the process of collating the required information and responding to the authorities, adding that the final report related to the action will be completed in line with prescribed procedures.
Despite the recent regulatory development, the company reported improved financial performance for the December quarter. For the third quarter of FY26, Sudarshan Pharma posted a net profit of Rs 4.15 crore, compared with Rs 3.9 crore in the same period a year earlier.
Revenue from operations rose sharply to Rs 168 crore in the quarter, up from Rs 115.65 crore a year ago. Earnings before interest, tax, depreciation and amortisation increased to Rs 23.4 crore from Rs 16.6 crore in the year-ago period.
However, operating margins came under pressure, with the EBITDA margin declining to 22.8 percent from 39.9 percent a year earlier.
In its filing, the company said it is focusing on increasing exports and expanding manufacturing-led sales. It also highlighted efforts to improve profit margins from the resale of active pharmaceutical ingredients in the domestic market, noting that these initiatives supported strong growth in profit after tax during FY25. (Source: IANS)
